<DOC>
	<DOCNO>NCT01012583</DOCNO>
	<brief_summary>BACKGROUND Treatment coronary atherosclerotic disease significantly advance interventional cardiology , advent coronary arterial stent . In comparison angioplasty alone , stent reduce incidence angiographic well clinical restenosis , recurrence angina , need coronary arterial bypass graft ( CABG ) surgery , repeat revascularization occurrence major adverse cardiac event ( MACE ) .However long-term success therapy limit occurrence in-stent restenosis . Despite effectiveness intracoronary stent maintain large luminal diameter , compare angioplasty alone , in-stent restenosis occur within 6 9 month stent placement 15 % 35 % patient . While stent reduce restenosis block vascular recoil remodeling , mechanical intervention alone incapable treat biological problem neointimal hyperplasia , particularly subset patient diabetes , long lesion small vessel disease.Drug-eluting stent ( DES ) develop viable method focus delivery anti-restenosis compound target lesion reduction restenosis . Of DES available result six ( 6 ) year clinical follow-up , sirolimus-eluting stent ( SES ) become current gold standard stent implantation . With advent use DES treat complex lesion longer lesion require use multiple stent use bifurcation lesion , risk stent thrombosis increase.Late stent thrombosis also report follow DES implantation.Long term treatment dual anti-platelet therapy follow stent implantation become solution use counteract risk stent thrombosis , solution come without 's risk expensive therapy . Another specific problem DES delay endothelization , may attribute factor prolong period thrombotic risk show pathological finding autopsy follow SES implantation . These examination show even 16 month , neointimal healing still incomplete approximately 20 % stent strut find uncovered . Questions arise problem late thrombosis delay endothelization stent strut DES could result permanent polymer use bond agent anti-restenosis compound stents.Intravascular Ultrasound ( IVUS ) along angiography technique use gain data DES point . Angiography 2 dimensional tool give view vessel IVUS give 3 dimensional view vessel . IVUS limitation , stent strut reflector sonic wave , shadow around behind struts occurs . IVUS also limit detect malapposition strut vessel wall especially area vessel wall strut small . RATIONALE Optical Coherence Tomography ( OCT ) optical analogue IVUS use infrared light source measure backscatter light . With technique high level resolution compare IVUS reported.OCT report able visualize detect atherosclerotic plaque assess accurately strut malapposition presence thickness neointimal hyperplasia compare IVUS . With question delay endothelization due permanent polymer probable risk late stent thrombosis , felt OCT post stent implantation may give accurate assessment stent strut endothelial coverage . This study design compare intimal hyperplasia follow implantation Excel DES biodegradable polymer vs. Cypher DES permanent polymer use OCT .</brief_summary>
	<brief_title>Optical Coherence TomOgraphy Assessment Drug-Eluting Stent</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Age 30 75 year . Binary stenosis &gt; 70 % de novo lesion native coronary artery . Reference lumen diameter proximal target lesion 2.5 mm &lt; 4.0 mm . Reference lesion length &lt; 30 mm . The target lesioin cover makimum two overlap stent single lesion . Written inform consent sign . Pregnant breast feed woman . Intolerance aspirin , clopidogrel ( Plavix® ) , ticlopidine ( Ticlid® ) , heparin , bivalirudin , stainless steel , contrast agent ( adequately premedicated ) , parylene , polylacticacid ( PLA ) , Biolimus A9 ( analogue ) . Lesion locate protect unprotected Left Main Coronary Artery . STEMI within 72 hour prior index procedure . The patient another drugeluting stent ( DES ) implant within 12 month prior index procedure . CCS Class III patient patient LVEF &lt; 40 % . Diffuse lesions &gt; 40 mm length . Renal impairment , serum creatinine &gt; 2.0 mg/dl . Complicated anatomy Chronic Total Occlusion ( CTO ) , Bifurcation Lesions ( side branch &gt; 2.5 mm ) Triple Vessel Disease ( TVD ) . Lesion predilated successfully . History gastritis and/or bleed history limit usual dual antiplatelet regime . Patient comorbid condition ( ) could limit his/her ability participate study , comply followup requirement impact scientific integrity study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Optical coherence tomography</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Biodegradable polymer</keyword>
	<keyword>Intimal</keyword>
	<keyword>Coverage</keyword>
	<keyword>ass intimal hyperplasia drug elute stent biodegradable polymer</keyword>
</DOC>